Tamada, Satoshi
Kondoh, Chihiro
Matsubara, Nobuaki
Mizuno, Ryuichi
Kimura, Go
Anai, Satoshi
Tomita, Yoshihiko
Oyama, Masafumi
Masumori, Naoya
Kojima, Takahiro
Matsumoto, Hiroaki
Chen, Mei
Li, Mengran
Matsuda, Kenji
Tanaka, Yoshinobu
Rini, Brian I.
Uemura, Hirotsugu
Funding for this research was provided by:
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA
Article History
Received: 25 May 2021
Accepted: 16 August 2021
First Online: 20 November 2021
Declarations
:
: Satoshi Tamada has received honoraria from MSD, Pfizer, Merck Biopharma, and Takeda. Chihiro Kondoh has nothing to disclose. Nobuaki Matsubara has received honoraria from Janssen, AstraZeneca, and Sanofi, and has received research funding from Janssen, AstraZeneca, Takeda, Lilly, Amgen, Astellas, Chugai, Bayer, MSD, Ono, Taiho, and Pfizer. Ryuichi Mizuno has received honoraria from Pfizer. Go Kimura has received honoraria from Ono, BMS, Bayer, Chugai, MSD, Pfizer, Janssen, Sanofi, and Esai, and has received research funding from Ono, BMS, MSD, Bayer, Chugai, Novartis, Astellas, AstraZeneca, Taiho, and Janssen. Satoshi Anai has nothing to disclose. Yoshihiko Tomita has nothing to disclose. Masafumi Oyama has nothing to disclose. Naoya Masumori has received honoraria from Takeda and Bayer, and has received research funding from Takeda, MSD, and Bristol-Myers Squibb. Takahiro Kojima has nothing to disclose. Hiroaki Matsumoto has nothing to disclose. Mei Chen is an employee of and owns stock in MSD. Mengran Li has nothing to disclose. Kenji Matsuda is an employee of MSD K.K., Tokyo, Japan and owns stock in Merck & Co., Inc. Yoshinobu Tanaka is an employee of and owns stock in MSD. Brian I. Rini has served as an advisor for BMS, Pfizer, GNE/Roche, Aveo, Synthorx, Compugen, Merck, Corvus, Surface Oncology, 3DMedicines, Aravive, Alkermes, Arrowhead, GSK, Shionogi, and Eisai, and has received research funding from Pfizer, Hoffman-LaRoche, Incyte, AstraZeneca, Taris, Seattle Genetics, Arrowhead Pharmaceuticals, Immunomedics, BMS, Mirati Therapeutics, Merck, Surface Oncology, Dragonfly Therapeutics, Aravive, and Exelixis. Hirotsugu Uemura has received honoraria from Pfizer, Bayer, MSD, BMS, and Janssen, and has received research funding from Takeda, Daiichi Sankyo, Astellas, Ono, AstraZeneca, Sanofi, and Kissei.